FibroGen terminates CFO Juan Graham and CMO Deyaa Adib as part of cost reduction plan

KYNTRA BIO, INC.

CFO Juan Graham and CMO Deyaa Adib given termination notice on Aug 30, 2024.
Graham's departure date: Dec 15, 2024; Adib's departure date: Nov 1, 2024.
Terminations are part of a cost reduction plan initiated Aug 2, 2024.
Company states decisions not due to any disagreement with executives.
Both will remain through transition periods.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Deyaa Adib

Chief Medical Officer

KYNB · KYNTRA BIO, INC.

Effective: 2024-11-01
Filed: September 6, 2024, 7:59 PM ET

the Company provided notice of termination to two executive officers on August 30, 2024, each of whom will remain with the Company through a transition period: Juan Graham, Chief Financial Officer and Deyaa Adib, M.D., Chief Medical Officer.

Departed

Juan Graham

Chief Financial Officer

KYNB · KYNTRA BIO, INC.

Effective: 2024-12-15
Filed: September 6, 2024, 7:59 PM ET

the Company provided notice of termination to two executive officers on August 30, 2024, each of whom will remain with the Company through a transition period: Juan Graham, Chief Financial Officer and Deyaa Adib, M.D., Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Deyaa Adib departed as Chief Medical Officer at KYNTRA BIO, INC..

Action: provided notice of termination
Role: Chief Medical Officer

Exact text from the filing

the Company provided notice of termination to two executive officers on August 30, 2024, each of whom will remain with the Company through a transition period: Juan Graham, Chief Financial Officer and Deyaa Adib, M.D., Chief Medical Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Juan Graham departed as Chief Financial Officer at KYNTRA BIO, INC..

Action: provided notice of termination
Role: Chief Financial Officer

Exact text from the filing

the Company provided notice of termination to two executive officers on August 30, 2024, each of whom will remain with the Company through a transition period: Juan Graham, Chief Financial Officer and Deyaa Adib, M.D., Chief Medical Officer.

View on SEC.gov

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-104395

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.